

ASX Announcement | 16 March 2021
Vioneering Technologies (ASX:VTI)

Special Meeting of Stockholders

Atlanta, Georgia, Monday, 15 March 2021 (Tuesday, 16 March 2021 Sydney time): US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses, **Vioneering Technologies, Inc (ASX: VTI)** ('Vioneering' or 'the Company'), reminds Stockholders and other interested parties that the Company is holding a Special Meeting of Stockholders on Wednesday 17 March 2021 at 10.00am AEDT (on Tuesday, 16 March 2021 at 7.00pm US EDT) (**Special Meeting**).

The Special Meeting is a virtual meeting and can be accessed online at:

<https://web.lumiagm.com>
using the Meeting ID of 396053728

Ends.

This release was authorized by the CEO, Stephen Snowdy, PhD

For more information, please contact:

Company	Investor and media relations
Stephen Snowdy CEO, Vioneering Technologies, Inc. Email: ssnowdy@vtivision.com	Julia Maguire The Capital Network M: +61 419 815 386 E: julia@thecapitalnetwork.com.au

About Vioneering Technologies, Inc.

Vioneering Technologies, Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Vioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.

Headquartered in the US, Vioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® Multifocal contact lens, and Vioneering has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the United States, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

To learn more, please visit: www.vtvision.com

Foreign ownership restrictions

Visioneering's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Any forward-looking statements are provided as a guide only and should not be relied upon as an indication or guarantee of future performance. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements. You should not place undue reliance on forward-looking statements because they speak only as of the date when made, and are subject to change without notice. Given the current uncertainties regarding the on-going impact of the COVID-19 on the trading conditions impacting Visioneering, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with Visioneering's expectations or that the effect of future developments on Visioneering will be those anticipated. Actual results may differ materially from what is expressed in this presentation and investors are cautioned not to place undue reliance on the current trading outlook.

Visioneering does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Visioneering may not actually achieve the plans, projections or expectations disclosed in forward-looking statements.